CSIMarket
 


Pluristem Therapeutics Inc  (PSTI)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

PSTI's Income from Cont. Operations Growth by Quarter and Year

Pluristem Therapeutics Inc's Income from Cont. Operations results by quarter and year




PSTI Income from Cont. Operations (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter June - -7.76 -8.98 -7.02
III Quarter March - -10.08 -1.53 -7.86
II Quarter December -6.37 -8.68 -8.23 -6.61
I Quarter September -7.14 -8.79 -7.39 -6.32
FY   -13.51 -35.31 -26.13 -27.81



PSTI Income from Cont. Operations second quarter 2020 Y/Y Growth Comment
Pluristem Therapeutics Inc in the second quarter recorded loss from continued operations of $ -6.37 millions.

According to the results reported in the second quarter, Pluristem Therapeutics Inc achieved the best Income from Cont. Operations growth in Biotechnology & Drugs industry. While Pluristem Therapeutics Inc' s Income from Cont. Operations no change of % ranks overall at the positon no. in the second quarter.




PSTI Income from Cont. Operations ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter June - - - -
III Quarter March - - - -
II Quarter December - - - -
I Quarter September - - - -
FY   - - - -

Financial Statements
Pluristem Therapeutics Inc's second quarter 2020 Income from Cont. Operations $ -6.37 millions PSTI's Income Statement
Pluristem Therapeutics Inc's second quarter 2019 Income from Cont. Operations $ -8.68 millions Quarterly PSTI's Income Statement
New: More PSTI's historic Income from Cont. Operations Growth >>


PSTI Income from Cont. Operations (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter June - - - -
III Quarter March - - - -
II Quarter December - - - -
I Quarter September - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Pluristem Therapeutics Inc's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PSTI's II. Quarter Q/Q Income from Cont. Operations Comment
Although Pluristem Therapeutics Inc in the II. Quarter 2020 admitted loss from continued operations of $ -6.37 millions, some analyst said, that those numbers point to improvement relative to the -7.14 millions in the first quarter.

Within Biotechnology & Drugs industry Pluristem Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Pluristem Therapeutics Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PSTI's II. Quarter Q/Q Income from Cont. Operations Comment
Despite the fact, that Pluristem Therapeutics Inc in the II. Quarter 2020 admitted loss from continued operations of $ -6.37 millions, it should be point out, that this show improvement in contrast to the -7.14 millions in the first quarter.

Within Biotechnology & Drugs industry Pluristem Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Pluristem Therapeutics Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Pluristem Therapeutics Inc's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
(Dec 31 2016)
12 Months Ending
(June 30. 2016)
Cumulative Income from Cont. Operations 12 Months Ending $ -31.35 $ -33.66 $ -35.31 $ -26.34 $ -23.25
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Pluristem Therapeutics Inc' has realized cumulative trailing twelve months loss from continued operations of $ -31 millions in the Dec 31 2019 period.

Pluristem Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Pluristem Therapeutics Inc' has realized cumulative trailing twelve months loss from continued operations of $ -31 millions in the Dec 31 2019 period.

Pluristem Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Drugs Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
PSTI's Income from Cont. Operations Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for PSTI's Competitors
Income from Cont. Operations Growth for Pluristem Therapeutics Inc's Suppliers
Income from Cont. Operations Growth for PSTI's Customers

You may also want to know
PSTI's Annual Growth Rates PSTI's Profitability Ratios PSTI's Asset Turnover Ratio PSTI's Dividend Growth
PSTI's Roe PSTI's Valuation Ratios PSTI's Financial Strength Ratios PSTI's Dividend Payout Ratio
PSTI's Roa PSTI's Inventory Turnover Ratio PSTI's Growth Rates PSTI's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Dec 31 2019 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Dec 31 2019
Prestige Consumer Healthcare Inc. -0.62 %$ -0.618 millions
Hill-rom Holdings, Inc. -5.69 %$ -5.687 millions
Quidel Corp -5.71 %$ -5.705 millions
Novartis Ag -6.95 %$ -6.953 millions
Catalent, Inc. -7.14 %$ -7.143 millions
Amgen Inc. -11.67 %$ -11.670 millions
Regeneron Pharmaceuticals, Inc. -11.85 %$ -11.846 millions
Petmed Express Inc -12.16 %$ -12.161 millions
Fonar Corp -13.47 %$ -13.466 millions
Phibro Animal Health Corp -19.35 %$ -19.352 millions
Fresenius Medical Care Ag & Co. Kgaa -27.61 %$ -27.611 millions
National Healthcare Corp -33.97 %$ -33.966 millions
Integra Lifesciences Holdings Corp -39.06 %$ -39.060 millions
Healthcare Services Group, Inc. -40.11 %$ -40.115 millions
Cyanotech Corp -40.63 %$ -40.625 millions
Enanta Pharmaceuticals, Inc. -48.32 %$ -48.318 millions
Becton, Dickinson And Company -53.67 %$ -53.667 millions
Lannett Co Inc -58.87 %$ -58.874 millions
Vertex Pharmaceuticals Inc -61.76 %$ -61.758 millions
Meridian Bioscience Inc -65.12 %$ -65.125 millions
Stryker Corp -65.24 %$ -65.244 millions
Ensign Group, Inc -68.06 %$ -68.064 millions
Iqvia Holdings Inc. -73.68 %$ -73.684 millions
Innoviva, inc. -78.51 %$ -78.507 millions
Shineco, Inc. -79.52 %$ -79.521 millions
Coherent, inc. -83.70 %$ -83.705 millions
Surmodics Inc -88.70 %$ -88.702 millions


             
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

ROK's Profile

Stock Price

ROK's Financials

Business Description

Fundamentals

Charts & Quotes

ROK's News

Suppliers

ROK's Competitors

Customers & Markets

Economic Indicators

ROK's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071